مشخصات مقاله:
عنوان فارسی مقاله:
مطالعه داخل موجود زنده (In vivo) و خارج از موجود زنده (آزمایشگاهی) (In virto) حفاظت عصبی نانوذرات لیپیدی جامد پر شده با دی متیل فومارات
عنوان انگلیسی مقاله:
In vitro and In vivo neuroprotective study of solid lipid nanoparticles loaded with dimethyl fumarate
کلمات کلیدی مقاله:
مدل کوپریزون، دی متیل فومارات، اسکلروسیز چندگانه، سلول های نوروبلاست SH-SY5Y
مناسب برای رشته های دانشگاهی زیر:
پزشکی – زیست شناسی
مناسب برای گرایش های دانشگاهی زیر:
علوم آزمایشگاهی – علوم سلولی و مولکولی
وضعیت مقاله انگلیسی و ترجمه:
مقاله انگلیسی را میتوانید به صورت رایگان با فرمت PDF با کلیک بر روی دکمه آبی، دانلود نمایید. برای ثبت سفارش ترجمه نیز روی دکلمه قرمز رنگ کلیک نمایید. سفارش ترجمه نیازمند زمان بوده و ترجمه این مقاله آماده نمیباشد و پس از اتمام ترجمه، فایل ورد تایپ شده قابل دانلود خواهد بود.
قسمتی از مقاله انگلیسی:
INTRODUCTION
The neurodegenerative process with damage to axons and oligodendrocytes is thought to be the cause of permanent neurological impairment and disability; this is a key feature of the disease multiple sclerosis (MS).[1,2] At present, most available MS therapies are thought to exert their effects through immunomodulatory or immunosuppressive functions.[3-5] Although these treatments are effective at inhibiting immune cell-driven inflammation and reducing the relapse rate, they are ineffective at controlling the predominantly neurodegenerative processes that occur later in the disease course.[6] Fumaric acid esters have been used since 1959 as a treatment for psoriasis.[7] Dimethyl fumarate (DMF) is currently approved by FDA as a first-line treatment for lowering relapse rates in MS.[8-11] DMF and monomethyl fumarate were able to activate the transcription factor nuclear factor-erythroid 2-related factor 2 pathways and subsequently induce the expression of antioxidant proteins.[12,13] Oxidative stress is one of the major factors in the pathogenesis of MS and is readily apparent within experimental autoimmune encephalomyelitis, a mouse model of MS, and also in MS lesions.[14] In recent years, many research has proved that new nanotechnology can be applied for the treatment and diagnosis of variety of immune-mediated diseases like MS. Solid lipid nanoparticles (SLNs) are a novel, nanocolloidal, biocompatible drug delivery systems with improved bioavailability and drug payload. These nanocolloidal systems have been recently explored for targeting central nervous system (CNS) and various neurological disorders. Taking cognizance to the challenges for neurological disorders, patient compliance, and enhanced efficacy, it was envisioned to formulate DMF loaded SLNs in an attempt to overcome these concerns. Further, the developed colloidal system was evaluated in vitro in human neuroblastoma cells and an established cuprizone animal model.